Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Core Insights - Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative precision medicines for oncology, specifically targeting serious conditions with unmet medical needs [1][3] - The company will present findings on its drug candidate NXP900 at the 2026 American Association for Cancer Research Meeting, highlighting its potential in combination therapies and overcoming drug resistance [1][2] Group 1: Company Overview - Nuvectis Pharma, Inc. is dedicated to the development of precision medicines for oncology [3] - NXP900 is an oral small molecule inhibitor targeting SRC Family of Kinases (SFK), including SRC and YES1, with a unique mechanism that inhibits both catalytic and scaffolding functions [3] Group 2: Upcoming Presentations - NXP900 will be featured in three presentations at the 2026 AACR Meeting, focusing on its synergy with KRAS inhibitors, overcoming resistance in cholangiocarcinoma, and restoring antitumor immunity in non-small cell lung cancer [2] - The presentations are scheduled for April 21st and April 22nd, 2026, in San Diego, CA [2]